Vaccination has saved more lives than any other medical advancement, but traditional methods of vaccine delivery are fast becoming outdated in our technological age. Dr Christine Rollier, James Martin Fellow on the Oxford Martin Programme on Vaccines will look at new methods of vaccine delivery technology that promise cheaper, safer and pain free implementation. Christine will be joined by Dr Pawan Dulal, a researcher in the Vaccine Delivery Technologies group at the Jenner Institute, who is developing a technology to render vaccines thermo-stable, a process that could revolutionise the global distribution of vaccine technology.
Join in on Twitter #tomorrowtech
About the speaker
Christine Rollier is a James Martin Fellow on the Oxford Martin Programme on Vaccines, a Jenner Investigator at the Oxford Vaccine Group, and a Post Doctoral Research Associate at the Department of Paediatrics, all at the University of Oxford.
She studied biochemistry and obtained her PhD at the University of Lyon I in 2000, studying DNA immunization as a therapeutic approach against chronic Hepatitis B Virus infection.
She trained in immunology, specialising in vaccine development at Institut National de la Sante et Recherche Medicale (INSERM), Lyon, France. She proceeded to work on novel vaccine development against Hepatitis C Virus chronic infection at the Biomedical Primate Research Center, The Netherlands for five years, before joining the Jenner Institute at the University of Oxford in 2007 as a senior immunologist to work on improvements of vaccine vectors against malaria.
She started her current position at the Oxford Vaccine Group in 2010, and her research activities, funded by the Oxford Biomedical Research Centre, Medical Research Council and charities, include pre-clinical and clinical investigation of new and improved vaccines against bacterial infections such as serogroup B meningococcus.
Pawan Dulal is a researcher in the Vaccine Delivery Technologies group at the Jenner Institute
He worked in the product and analytical development groups of two biotech companies in the past six years before joining the Jenner Institute.
His current focus is the development of heat stable vaccine for their efficient distribution in the developing world. He is exploring the potential of the technology in thermostabilisation of a new malaria vaccine, Newcastle disease vaccine (for poultry), Rift Valley fever vaccine (cattle and sheep) and other commercially available vaccines